Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease
- PMID: 9399211
- DOI: 10.1002/mds.870120609
Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease
Abstract
The molecular characteristics of midbrain dopamine (DA) neurons have been extensively studied in Parkinson's disease (PD). No such studies of the characteristics of midbrain DA neurons in Alzheimer's disease (AD) or Alzheimer's disease with parkinsonism (AD/Park) have been published. We examined the levels of tyrosine hydroxylase (TH) protein, and the expression of TH and dopamine transporter (DAT) mRNAs, in midbrain neurons of PD, AD, and AD/Park cases. In PD, the loss of TH protein in the ventral tier of the substantia nigra pars compacta (SNpc) of the PD group in accompanied by severe losses in the number of neurons that express TH mRNA and DAT mRNA (74% loss). Remaining neurons show a shift to higher concentrations of TH mRNA but a shift to lower concentrations of DAT mRNA per cell. Hence, there is evidence that compensation in the remaining neurons can elevate concentrations of TH mRNA and lower DAT mRNA. Alternatively, there may be a predilection for a loss of neurons with high levels of DAT mRNA and low TH mRNA levels within the SNpc of PD cases. There was no change in TH protein but an elevation of TH mRNA concentrations per neuron without any change in concentrations of DAT mRNA in the AD group. The AD/Park group did not exhibit changes in the level of TH protein, but showed a small loss (26%) of neurons in the SNpc and a greater loss in other regions of the midbrain (43-53%). Remaining DA neurons showed a marked shift to lower concentrations of DAT mRNA per neuron and a nonsignificant shift in cellular concentration of TH mRNA to higher levels. This is consistent with our previous work showing that with AD/Park there is a significant reduction in the number of DAT sites located on DA terminals in the striatum, but the midbrain neurons have not died. Our results indicate that the differential regulation of mRNAs encoding TH and DAT is similar in the parkinsonian disorders (PD and AD/Park) even though the degree of cell death is very different. This might suggest that compensatory events occur in these DA neurons in AD/Park that are similar to those in PD and that result in differential effects on mRNAs encoding TH and DAT proteins.
Similar articles
-
Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.Ann Neurol. 1995 Mar;37(3):300-12. doi: 10.1002/ana.410370306. Ann Neurol. 1995. PMID: 7695230
-
Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity.J Comp Neurol. 1995 Nov 20;362(3):400-10. doi: 10.1002/cne.903620308. J Comp Neurol. 1995. PMID: 8576447
-
[Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].Zhongguo Zhen Jiu. 2009 May;29(5):391-4. Zhongguo Zhen Jiu. 2009. PMID: 19489498 Chinese.
-
Dopaminergic neurons intrinsic to the striatum.J Neurochem. 2007 Jun;101(6):1441-7. doi: 10.1111/j.1471-4159.2006.04430.x. Epub 2007 Feb 5. J Neurochem. 2007. PMID: 17286588 Review.
-
Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?Int Rev Neurobiol. 2007;82:235-46. doi: 10.1016/S0074-7742(07)82012-5. Int Rev Neurobiol. 2007. PMID: 17678964 Review.
Cited by
-
Monoaminergic System Modulation in Depression and Alzheimer's Disease: A New Standpoint?Front Pharmacol. 2019 May 17;10:483. doi: 10.3389/fphar.2019.00483. eCollection 2019. Front Pharmacol. 2019. PMID: 31156428 Free PMC article. Review.
-
Substantia nigral dopamine transporter uptake in dementia with Lewy bodies.NPJ Parkinsons Dis. 2023 Jun 9;9(1):88. doi: 10.1038/s41531-023-00534-9. NPJ Parkinsons Dis. 2023. PMID: 37296236 Free PMC article.
-
Neuronal threshold functions: Determining symptom onset in neurological disorders.Prog Neurobiol. 2024 Nov;242:102673. doi: 10.1016/j.pneurobio.2024.102673. Epub 2024 Oct 9. Prog Neurobiol. 2024. PMID: 39389338 Free PMC article. Review.
-
Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms.Geroscience. 2025 Feb;47(1):457-482. doi: 10.1007/s11357-024-01359-x. Epub 2024 Sep 27. Geroscience. 2025. PMID: 39331291 Free PMC article. Review.
-
Unique Pathology in the Locus Coeruleus of Individuals with Down Syndrome.J Alzheimers Dis. 2024;101(2):541-561. doi: 10.3233/JAD-240043. J Alzheimers Dis. 2024. PMID: 39213062 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous